Corrigendum to 'sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours'
Name:
PIIS0959804924007172.pdf
Size:
290.0Kb
Format:
PDF
Description:
Found with Open Access Button
Authors
Hernando, J.Roca-Herrera, M.
García-Álvarez, A.
Raymond, E.
Ruszniewski, P.
Kulke, M. H.
Grande, E.
Carbonero, R. G.
Castellano, D.
Salazar, R.
Ibrahim, T.
Teule, A.
Alonso, V.
Fazio, N.
Valle, Juan W
Tafuto, S.
Carmona, A.
Navarro, V.
Capdevila, J.
Affiliation
Division of Cancer Sciences, University of Manchester & Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.Issue Date
2024
Metadata
Show full item recordCitation
Hernando J, Roca-Herrera M, García-Álvarez A, Raymond E, Ruszniewski P, Kulke MH, et al. Corrigendum to "Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours" [Eur J Cancer 188 (2023) 39-48]. European journal of cancer (Oxford, England : 1990). 2024 May;203:114061. PubMed PMID: 38609739. Epub 2024/04/13. eng.Journal
European Journal of CancerDOI
10.1016/j.ejca.2024.114061PubMed ID
38609739Additional Links
https://dx.doi.org/10.1016/j.ejca.2024.114061Type
OtherLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.ejca.2024.114061
Scopus Count
Collections
Related articles
- Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours.
- Authors: Hernando J, Roca-Herrera M, García-Álvarez A, Raymond E, Ruszniewski P, Kulke MH, Grande E, García-Carbonero R, Castellano D, Salazar R, Ibrahim T, Teule A, Alonso V, Fazio N, Valle JW, Tafuto S, Carmona A, Navarro V, Capdevila J
- Issue date: 2023 Jul
- [Expert dialogue: neuroendocrine tumours of the lungs and gastroenteropancreatic system].
- Authors: Hörsch D, Sayeg Y, Bonnet R, Kaemmerer D, Presselt N, Baum RP
- Issue date: 2012 Jan
- Corrigendum to 'A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours' [Eur J Cancer 104 (November 2018) 1-8].
- Authors: Gazzah A, Boni V, Soria JC, Calles A, Even C, Doger B, Mahjoubi L, Bahleda R, Ould-Kaci M, Esler A, Nazabadioko S, Calvo E
- Issue date: 2019 Sep
- Management of Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEPNETs): A Review.
- Authors: Pasricha G, Padhi P, Daboul N, Monga DK
- Issue date: 2017 Nov
- Matching-adjusted indirect treatment comparison of [(177)Lu]Lu-DOTA-TATE, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours: Relative effectiveness of [(177)Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumours.
- Authors: Khan MS, Stamp E, Sammon C, Brabander T, de Herder WW, Pavel ME
- Issue date: 2021 Nov